siRNA drug targeting Phosphomevalonate kinase (PMVK) for


PMVK (phosphomevalonate kinase) is a cytosolic enzyme, known to be involved in isopentenyl diphosphate biosynthesis via mevalonate pathway. PMVK catalyzes the conversion of mevalonate 5-phosphate into mevalonate 5-diphosphate in the fifth reaction of the cholesterol biosynthetic pathway. Recently, we have confirmed that PMVK overexpression is correlated with poor prognosis. Based on our preliminary results, we expect that Mevisiran [LNP based-PMVK siRNA drug] significantly improves the patient's survival in combinations of chemo-/radio-therapeutic agents.